1
Clinical Trials associated with NKC007 / Not yet recruitingPhase 1 NKC007细胞注射液治疗急性髓系白血病患者的Ⅰ期临床试验
[Translation] Phase I clinical trial of NKC007 cell injection for the treatment of patients with acute myeloid leukemia
主要研究目的:评估NKC007细胞注射液治疗复发/难治性AML患者的安全性和耐受性。次要研究目的:初步评估NKC007细胞注射液治疗复发/难治性AML患者的有效性;评估NKC007细胞注射液在复发/难治性急性髓系白血病患者中的药代动力学(PK)和药效动力学(PD)特征。
[Translation] Primary study objective: To evaluate the safety and tolerability of NKC007 cell injection in patients with relapsed/refractory AML. Secondary study objectives: To preliminarily evaluate the efficacy of NKC007 cell injection in patients with relapsed/refractory AML; and to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of NKC007 cell injection in patients with relapsed/refractory acute myeloid leukemia.
100 Clinical Results associated with NKC007
100 Translational Medicine associated with NKC007
100 Patents (Medical) associated with NKC007
100 Deals associated with NKC007